Clinical Trial SuccessThe therapeutic regimen under evaluation has shown impressive results, with a 62% overall survival rate and an 85% disease control rate in the GOBLET trial.
Regulatory AdvancementsOncolytics Biotech is leveraging its Fast Track and Orphan Drug designations to accelerate consultation with the FDA and EMA regulators, aiming for an efficient regulatory path forward for its lead program.
Strategic FocusWith a new leadership team, a clear strategy, and a compelling survival signal in hand—Oncolytics is building momentum toward a key inflection point in 2025.